ProCE Banner Activity

Current Landscape in Ovarian Cancer: PARP Inhibitors and Targeted Therapy

Text Module

Explore this expert discussion of PARP inhibition in ovarian cancer, including current best practices, combinations with targeted agents, and future directions, and then download the slideset containing all the key data.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Released: December 03, 2020

Expiration: December 02, 2021

No longer available for credit.

Share

Supporters

GlaxoSmithKline LLC

Learning Objectives


  • Assess the improvement in risk of progression from the addition of PARP inhibitor–based frontline treatment of ovarian cancer in selected and unselected patients 
  • Plan maintenance therapy for patients with BRCA mutations or other defects in homologous recombination repair 
  • Discuss patient and tumor characteristics that identify candidates for treatment with frontline PARP inhibitors 
  • Evaluate the differences between the PARP inhibitors with regard to evolving indications, dosing, administration, efficacy, and treatment-related symptoms

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.